Maxim Group set a $14.00 target price on Abeona Therapeutics Inc. (NASDAQ:ABEO) in a research report sent to investors on Tuesday morning. The firm currently has a a buy rating on the biopharmaceutical company’s stock.
Several other analysts have also recently commented on the company. Cantor Fitzgerald restated a buy rating and issued a $21.00 price target on shares of Abeona Therapeutics in a report on Friday, October 21st. Zacks Investment Research upgraded Abeona Therapeutics from a sell rating to a hold rating in a report on Tuesday, October 18th. HC Wainwright restated a buy rating and issued a $17.00 price target on shares of Abeona Therapeutics in a report on Thursday, October 6th. Finally, FBR & Co restated a positive rating and issued a $15.00 price target on shares of Abeona Therapeutics in a report on Wednesday, October 5th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of Buy and an average price target of $14.50.
Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at 7.05 on Tuesday. The company’s 50 day moving average is $6.45 and its 200-day moving average is $3.89. Abeona Therapeutics has a 1-year low of $2.05 and a 1-year high of $9.44. The stock’s market capitalization is $236.49 million.
Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings data on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by $0.06. Abeona Therapeutics had a negative return on equity of 30.84% and a negative net margin of 2,177.03%. Equities analysts anticipate that Abeona Therapeutics will post ($0.74) earnings per share for the current fiscal year.
In other news, Director Todd Wider acquired 5,000 shares of Abeona Therapeutics stock in a transaction dated Tuesday, September 20th. The shares were acquired at an average cost of $5.48 per share, with a total value of $27,400.00. Following the purchase, the director now directly owns 75,000 shares of the company’s stock, valued at approximately $411,000. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 13.00% of the stock is owned by insiders.
Several institutional investors have recently added to or reduced their stakes in the stock. Royce & Associates LP raised its position in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock valued at $963,000 after buying an additional 76,678 shares in the last quarter. Sabby Management LLC raised its position in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock valued at $855,000 after buying an additional 34,108 shares during the period. Finally, Geode Capital Management LLC raised its position in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock valued at $180,000 after buying an additional 10,082 shares during the period. 19.96% of the stock is currently owned by institutional investors and hedge funds.
Abeona Therapeutics Company Profile